AbbVie Inc.
Business Model Analysis
How AbbVie Makes Money
Annual Revenue: $61.2B
AbbVie generates revenue primarily through Biopharmaceutical, with roughly $61.2B in annual revenue.
Core Growth Engine: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuro...
Revenue Model & Pricing
AbbVie Inc. is a research-based biopharmaceutical enterprise dedicated to discovering and marketing advanced specialty therapeutics. Commercial operations span four primary therapeutic franchises: Immunology (accounting for the largest portion of sales), Oncology, Neuroscience, and Aesthetics. Flagship immunology blockbusters include Skyrizi (risankizumab for plaque psoriasis, psoriatic arthritis, and Crohn's disease) and Rinvoq (upadacitinib for rheumatoid arthritis and ulcerative colitis), which were developed to replace revenue from the loss of exclusivity on Humira. The Aesthetics division, anchored by Allergan, includes Botox Cosmetic and Juvéderm dermal fillers. The Neuroscience franchise is led by Vraylar (bipolar and depression) and Qulipta (migraine prevention), while Oncology features Imbruvica and Venclexta.
Core Revenue Streams
Immunology Portfolio
49.7%FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.
Neuroscience Portfolio
17.6%FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.
Oncology Portfolio
10.9%FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.
Aesthetics Portfolio
7.9%FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.
Other Products and Revenue
13.9%The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.
Growth Strategy
AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
How AbbVie Makes Money: FAQ
How does AbbVie make money?
AbbVie sells prescription medicines and Allergan Aesthetics products globally.
What were AbbVie's main FY2025 portfolios?
Immunology generated $30.406 billion, neuroscience $10.767 billion, oncology $6.655 billion, and aesthetics $4.860 billion.
How important were Skyrizi and Rinvoq in FY2025?
Skyrizi and Rinvoq generated $25.866 billion combined, or about 42.3 percent of FY2025 net revenue.
How does AbbVie add pipeline assets?
AbbVie combines internal research with licensing and acquisitions. ImmunoGen added Elahere and antibody-drug conjugate programs, while Cerevel added neuroscience programs.
How does AbbVie make money without Humira?
Following Humira's U.S. patent expiration, AbbVie heavily diversified its business model by acquiring Allergan (gaining Botox aesthetics) and successfully launching next-generation immunology blockbusters Skyrizi and Rinvoq.
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore AbbVie
Core profile pages, founders and related research hubs for this company.